JP2015506696A - ＴＧＦ−β２発現を抑制するｓｈＲＮＡ - Google Patents

ＴＧＦ−β２発現を抑制するｓｈＲＮＡ Download PDF

Info

Publication number: JP2015506696A
Authority: JP; Japan
Prior art keywords: shrna; tgf; adenovirus; seq; expression
Prior art date: 2012-01-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2014555484A

Other languages

English (en)

Japanese (ja)

Inventor

ジェ・ジン・ソン

ジョ・ハン・キム

セ・ウン・オー

Original Assignee

インダストリー−アカデミック・コーポレーション・ファウンデーション・ヨンセイ・ユニヴァーシティ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-31

Filing date

2013-01-31

Publication date

2015-03-05

2013-01-31 Application filed by インダストリー−アカデミック・コーポレーション・ファウンデーション・ヨンセイ・ユニヴァーシティ filed Critical インダストリー−アカデミック・コーポレーション・ファウンデーション・ヨンセイ・ユニヴァーシティ

2013-01-31 Priority claimed from PCT/KR2013/000791 external-priority patent/WO2013115579A1/ko

2015-03-05 Publication of JP2015506696A publication Critical patent/JP2015506696A/ja

Status Pending legal-status Critical Current

Links

108091027967 Small hairpin RNA Proteins 0.000 title claims abstract description 99
101800000304 Transforming growth factor beta-2 Proteins 0.000 title claims abstract description 73
102000011117 Transforming Growth Factor beta2 Human genes 0.000 title claims abstract description 71
239000004055 small Interfering RNA Substances 0.000 claims abstract description 92
239000000203 mixture Substances 0.000 claims abstract description 19
230000000259 anti-tumor effect Effects 0.000 claims abstract description 16
241000701161 unidentified adenovirus Species 0.000 claims description 62
239000013604 expression vector Substances 0.000 claims description 21
238000003259 recombinant expression Methods 0.000 claims description 15
239000004480 active ingredient Substances 0.000 claims description 11
239000013598 vector Substances 0.000 claims description 11
210000004027 cell Anatomy 0.000 description 39
108020004414 DNA Proteins 0.000 description 33
206010028980 Neoplasm Diseases 0.000 description 29
230000006801 homologous recombination Effects 0.000 description 25
238000002744 homologous recombination Methods 0.000 description 25
108020004999 messenger RNA Proteins 0.000 description 20
238000003753 real-time PCR Methods 0.000 description 19
241000699666 Mus <mouse, genus> Species 0.000 description 18
239000013605 shuttle vector Substances 0.000 description 18
230000000694 effects Effects 0.000 description 16
238000000034 method Methods 0.000 description 16
201000011510 cancer Diseases 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
239000013612 plasmid Substances 0.000 description 10
230000001629 suppression Effects 0.000 description 10
101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 description 9
241000700605 Viruses Species 0.000 description 9
238000012790 confirmation Methods 0.000 description 9
108091008146 restriction endonucleases Proteins 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 8
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 8
230000009368 gene silencing by RNA Effects 0.000 description 8
101100206411 Mus musculus Tgfb2 gene Proteins 0.000 description 7
230000000295 complement effect Effects 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
230000008569 process Effects 0.000 description 7
230000002441 reversible effect Effects 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
230000007017 scission Effects 0.000 description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
101150108210 IX gene Proteins 0.000 description 5
108020004459 Small interfering RNA Proteins 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000030279 gene silencing Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000013603 viral vector Substances 0.000 description 5
238000002965 ELISA Methods 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
241001123946 Gaga Species 0.000 description 4
206010027476 Metastases Diseases 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
150000007523 nucleic acids Chemical group 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
206010018910 Haemolysis Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
102000056172 Transforming growth factor beta-3 Human genes 0.000 description 3
108090000097 Transforming growth factor beta-3 Proteins 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000005520 cutting process Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
230000008588 hemolysis Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000001743 silencing effect Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000009466 transformation Effects 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 2
241000701149 Human adenovirus 1 Species 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000713666 Lentivirus Species 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000012226 gene silencing method Methods 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000009545 invasion Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
229940072041 transforming growth factor beta 2 Drugs 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000005909 tumor killing Effects 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
238000012418 validation experiment Methods 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000003661 Ribonuclease III Human genes 0.000 description 1
108010057163 Ribonuclease III Proteins 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
102000000763 Survivin Human genes 0.000 description 1
108010002687 Survivin Proteins 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000003172 anti-dna Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000037451 immune surveillance Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000005642 phosphothioate group Chemical group 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000011160 research Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
FNCMIJWGZNHSBF-UHFFFAOYSA-N trabedersen Chemical compound CC1=CN(C2CC(O)C(COP(=O)(S)OC3CC(OC3COP(=O)(S)OC4CC(OC4COP(=O)(S)OC5CC(OC5COP(=O)(S)OC6CC(OC6COP(=O)(S)OC7CC(OC7COP(=O)(S)OC8CC(OC8COP(=O)(S)OC9CC(OC9COP(=O)(S)OC%10CC(OC%10COP(=O)(S)OC%11CC(OC%11COP(=O)(S)OC%12CC(OC%12COP(=O)(S)OC%13CC(OC%13COP(=O)(S)OC%14CC(OC%14COP(=O)(S)OC%15CC(OC%15CO)N%16C=CC(=NC%16=O)N)n%17cnc%18C(=O)NC(=Nc%17%18)N)n%19cnc%20C(=O)NC(=Nc%19%20)N)N%21C=CC(=NC%21=O)N)n%22cnc%23c(N)ncnc%22%23)N%24C=C(C)C(=O)NC%24=O)n%25cnc%26C(=O)NC(=Nc%25%26)N)N%27C=C(C)C(=O)NC%27=O)N%28C=CC(=NC%28=O)N)N%29C=C(C)C(=O)NC%29=O)n%30cnc%31c(N)ncnc%30%31)N%32C=C(C)C(=O)NC%32=O)N%33C=C(C)C(=O)NC%33=O)O2)C(=O)NC1=O.CC%34=CN(C%35CC(OP(=O)(S)OCC%36OC(CC%36OP(=O)(S)OCC%37OC(CC%37OP(=O)(S)OCC%38OC(CC%38O)n%39cnc%40c(N)ncnc%39%40)N%41C=C(C)C(=O)NC%41=O)n%42cnc%43C(=O)NC(=Nc%42%43)N)C(COP(=O)S)O%35)C(=O)NC%34=O FNCMIJWGZNHSBF-UHFFFAOYSA-N 0.000 description 1
229950002824 trabedersen Drugs 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
238000012795 verification Methods 0.000 description 1
230000007998 vessel formation Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Oncology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2014555484A 2012-01-31 2013-01-31 ＴＧＦ−β２発現を抑制するｓｈＲＮＡ Pending JP2015506696A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
KR20120009811		2012-01-31
KR10-2012-0009811		2012-01-31
KR1020130010233A KR101420564B1 (ko)	2012-01-31	2013-01-30	ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ
KR10-2013-0010233		2013-01-30
PCT/KR2013/000791 WO2013115579A1 (ko)	2012-01-31	2013-01-31	ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ

Publications (1)

Publication Number	Publication Date
JP2015506696A true JP2015506696A (ja)	2015-03-05

Family

ID=49215002

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2014555484A Pending JP2015506696A (ja)	2012-01-31	2013-01-31	ＴＧＦ−β２発現を抑制するｓｈＲＮＡ

Country Status (3)

Country	Link
JP (1)	JP2015506696A (ko)
KR (1)	KR101420564B1 (ko)
CN (1)	CN104245936B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015152609A1 (ko) *	2014-03-31	2015-10-08	연세대학교 산학협력단	ＧＭ－ＣＳＦ 유전자; 데코린 유전자; ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ; 및 ＦｏｘＰ３ 발현을 억제하는 ｓｈＲＮＡ를 포함하는 항종양 조성물
KR101713407B1 (ko) *	2014-03-31	2017-03-07	연세대학교 산학협력단	아데노바이러스 감염 및 복제가 가능한 흑색종 세포주
EP3388522B1 (en) *	2015-12-08	2020-08-12	University-Industry Foundation, Yonsei University	Antitumor composition comprising gm-csf gene, flt3l-trail fusion gene, shrna inhibiting tgf- expression, and shrna inhibiting hsp expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011154542A1 (en) *	2010-06-11	2011-12-15	Artisense Pharma Gmbh	Method for selective oligonucleotide modification

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009522303A (ja) *	2005-12-30	2009-06-11	ウェイ−ウーヒー，	瘢痕を生じない皮膚創傷治癒を促進するｓｉＲＮＡ組成物および創傷処置の方法
CN101974529B (zh) *	2010-09-21	2013-04-03	南京大学（苏州）高新技术研究院	含自由三磷酸基团的TGF-β特异性siRNA及其应用

2013
- 2013-01-30 KR KR1020130010233A patent/KR101420564B1/ko active IP Right Grant
- 2013-01-31 JP JP2014555484A patent/JP2015506696A/ja active Pending
- 2013-01-31 CN CN201380007620.1A patent/CN104245936B/zh active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011154542A1 (en) *	2010-06-11	2011-12-15	Artisense Pharma Gmbh	Method for selective oligonucleotide modification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015033218; Ｃａｎｃｅｒ　Ｒｅｓ，　２００９，　ｖｏｌ．６９，　ｎｏ．３，　ｐ．８２８-８３５ *
JPN6015033222; ｓｉＤｉｒｅｃｔ　ｖｅｒｓｉｏｎ　２．０　ｈｉｇｈｌｙ　ｅｆｆｅｃｔｉｖｅ，　ｔａｒｇｅｔ　ｓｐｅｃｉｆｉｃ　ｓｉＲＮＡ　ｏｎｌｉｎｅ　ｄｅｓｉｇｎ　ｓｉｔｅ２００９，　［Ｒｅｔｒｉｅｖｅｄ　ｏｎ　Ａｕｇｕｓｔ　１３，　２０１５］, ＵＲＬ：ｈｔｔｐ：／／ｓｉｄｉｒｅｃｔ２．ｒｎａｉ．ｊｐ／ *

Also Published As

Publication number	Publication date
CN104245936B (zh)	2016-04-06
CN104245936A (zh)	2014-12-24
KR101420564B1 (ko)	2014-07-17
KR20130088792A (ko)	2013-08-08

Legal Events

Date

Code

Title

Description

2015-08-18

A131

Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150817

2016-02-02

A02

Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160201

Publication	Publication Date	Title
CN107406852B (zh)	2021-06-11	用于莱伯氏先天性黑蒙的寡核苷酸疗法
JP5383186B2 (ja)	2014-01-08	Ｈ１９をダウンレギュレートする核酸薬剤、及びそれを使用する方法
EP2850184A1 (en)	2015-03-25	Compositions and methods for modulating gene expression
US20100086526A1 (en)	2010-04-08	Nucleic acid constructs and methods for specific silencing of h19
US11304970B2 (en)	2022-04-19	EGFR gene expression-suppressing siRNA, precursor of same, and applications thereof
US9222090B2 (en)	2015-12-29	RNA interference target for treating AIDS
CN109563513B (zh)	2022-07-22	一种抑制K-RAS基因表达的siRNA及其前体和应用
CN111876421A (zh)	2020-11-03	靶向KrasG12D突变转录本的gRNA序列、载体及其应用
CN113694077A (zh)	2021-11-26	用于伤口愈合的短小发夹rna与微rna的组合物以及方法
JP2015506696A (ja)	2015-03-05	ＴＧＦ−β２発現を抑制するｓｈＲＮＡ
KR101286053B1 (ko)	2013-07-19	ＴＧＦ－β１ 발현을 억제하는 ｓｈＲＮＡ
JP6347433B2 (ja)	2018-06-27	Ｈｐｖ感染に係わる癌の治療用組成物
KR101374585B1 (ko)	2014-03-17	ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ
WO2021218802A1 (zh)	2021-11-04	可受微小rna调控的分离的重组溶瘤痘病毒及其应用
US11498976B2 (en)	2022-11-15	Viral complex comprising shRNA and anti-EpCAM antibody and uses thereof
KR101683964B1 (ko)	2016-12-09	Daxx의 발현을 억제하는 핵산 분자, TRAIL 유전자 및 Bcl-xL 의 발현을 억제하는 핵산 분자를 포함하는 재조합 발현 벡터
CN115927472A (zh)	2023-04-07	一种抗vegf抗体体内表达系统的构建和应用
WO2013115579A1 (ko)	2013-08-08	ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ
JP4505566B2 (ja)	2010-07-21	肺癌治療剤
US20210332364A1 (en)	2021-10-28	siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
CN107184984A (zh)	2017-09-22	Rpl10的抑制剂在制备治疗卵巢癌的药物中的应用
JP2010521460A (ja)	2010-06-24	癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制
WO2023023597A1 (en)	2023-02-23	Virus-like particle
CN117778474A (zh)	2024-03-29	一种基于CRISPR-Cas13a靶向敲低癌基因的表达载体及其应用
CN116515833A (zh)	2023-08-01	Acvr1c抑制剂在治疗结直肠癌中的应用